Products Affected - Description
All presentations are currently available
Reason for the Shortage
- Actavis states the reason for the shortage of Namenda XR capsules was manufacturing delay.
- There are several other manufacturers of memantine immediate release tablets and these were not affected by the shortage.
Namenda XR oral capsule, Actavis (formerly Forest)
7 mg, 30 count (NDC 00456-3407-33)
14 mg, 30 count (NDC 00456-3414-33)
14 mg, 90 count (NDC 00456-3414-90)
14 mg, unit-dose 100 count (NDC 00456-3414-63)
21 mg, 30 count (NDC 00456-3421-33)
28 mg, 30 count (NDC 00456-3428-33)
28 mg, 90 count (NDC 00456-3428-90)
28 mg, unit-dose 100 count (NDC 00456-3428-63)
Titration Pack 28 count (NDC 00456-3400-29)
Estimated Resupply Dates
Actavis has all Namenda XR presentations available.
February 5, 2016; December 15, October 29, August 6, 4 and 3, May 8, April 20, January 27 and 6, 2015; November 26 and 3, September 29 and 3, August 7, June 23, March 31, February 19, 2014, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins